AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population

RecruitingNAAges 2 Years - 12 YearsAllUniversidad Autónoma de Aguascalientes
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to evaluate the protective effect of glycomacropeptide on the clinical signs and symptoms of atopic dermatitis in children aged 2 to 12 years, and to determine if topical administration of glycomacropeptide is associated with a lower colonization by Staphylococcus species on the skin. The main questions that it aims to answer are: * Does glycomacropeptide reduce the signs and symptoms related to atopic dermatitis in the pediatric population? * Does glycomacropeptide modify the colonization of Staphylococcus species in atopic dermatitis lesions in the pediatric population? Researchers will compare an emollient cream containing glycomacropeptide with an emollient cream without glycomacropeptide to evaluate whether treatment with glycomacropeptide achieves a greater reduction in the clinical severity and pruritus of atopic dermatitis and a lower bacterial

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Children aged between 2 and 12 years. * Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka criteria. * Mild atopic dermatitis with SCORAD \<25 points. * Written informed consent signed by parents or legal guardian. Exclusion Criteria: * Age younger than 2 years or older than 12 years. * Moderate to severe atopic dermatitis (SCORAD \>25 points). * Presence of other dermatoses in addition to atopic dermatitis. * Background of hypersensitivity or anaphylaxis to any components of the vehicle cream. * Allergy or hypersensitivity to glycomacropeptide. * Inability to attend follow-up medical consultations or to adhere to the treatment schedule. * Any clinical reason determined by the clinical investigator that makes the child unsuitable for the study.
💊

What it tests

  • glycomacropeptide
  • emollient cream
📍

Where

1 site
Universidad Autónoma de Aguascalientes
Aguascalientes, Mexico
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy